Axitinib (Inlyta)

From - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Tyrosine kinase inhibitor of vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3, which interferes with tumor angiogenesis, growth, and cancer progression, at picomolar concentrations. Inhibits PDGFRA, PDGFRB and c-kit at nanomolar concentrations.[1][2][3][4]
Route: PO
Extravasation: n/a

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 1/27/2012: Initial FDA approval "for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy."

Also known as

  • Code names: AG013736, AG-013736
  • Brand name: Inlyta


  1. 1.0 1.1 1.2 Axitinib (Inlyta) package insert
  2. Axitinib (Inlyta) package insert (locally hosted backup)
  3. Inlyta manufacturer's website
  4. Matthew Stenger. What You Need to Know About Axitinib, New Agent for Treating Advanced Renal Cell Carcinoma. ASCO Post, March 15, 2012, Volume 3, Issue 5.
  5. Inlyta Side Effect Tips & Videos (Pfizer)
  6. Axitinib (Inlyta) patient drug information (Chemocare)
  7. Axitinib (Inlyta) patient drug information (UpToDate)